iSpecimen names Yuying Liang CFO, unveils plan to expand cancer biospecimen procurement

iSpecimen Inc.

Appointed Yuying Liang as CFO effective Dec 13, 2024; monthly fee of $25k under engagement with his professional corp.
Strategic 2025 initiatives focus on procuring high-demand cancer biospecimens through expanded partnerships.
Plans to establish referral program with international genomic sequencing partner; iSpecimen to be preferred provider.
Targeting new partnerships with U.S. cancer centers for domestic blood products, with 2025 launch.
Will expand portfolio with remnant biofluid offerings from recently partnered sites, including diagnostic codes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.